Best Voip Service Providers Chart
		$9.95 - $16.58
		$19.99 - $39.99
		$9.95 - $15.95

Cellzome Announces Further Extension of Molecular Pathway Collaboration

Cellzome Inc. announced today that its research collaboration with Novartis has been extended until 30 June 2008.

Cellzome will continue to apply its proprietary technology to identify tractable therapeutic targets in several disease-relevant pathways, and to the identification of pharmacological targets, and potential off-target effects, of active Novartis compounds. Novel drug discovery projects have resulted from this work.

Tim Edwards, Cellzome's CEO, said: "Our two teams have been working very well together and continue to make progress and create novel intellectual property. I look forward to further progress with Novartis, as Cellzome continues to integrate its technology into the drug discovery process."

About the Collaboration

In 2004, Cellzome and Novartis entered into a collaboration that combines Cellzome's experience in chemical proteomics and pathway mapping with Novartis' insights into particular disease pathways and its expertise in sensitized cellular screens. The companies are charting the physical and functional protein maps of key cellular pathways of a variety of diseases, with the potential to select the best protein targets within these pathways for the development of new drug candidates.

Cellzome's chemical proteomics expertise is also helping identify the role of active Novartis compounds in disease and their potential side effects. The work is being conducted between Cellzome's Heidelberg operations and Novartis' Developmental and Molecular Pathways group based in Cambridge MA. Novartis has made an equity investment in Cellzome Inc. and contributes research funding. There are also lead compound development options for both companies in exchange for licenses, milestone payments and royalties.

Author:  

Email:    

Topic:    

Content: